Opinion|Videos|October 17, 2024
Advocacy Groups and Integration of Wellness Strategies into Treatment for Parkinson’s Disease
Author(s)Stuart H. Isaacson, MD, FAAN
Key Takeaways
- Integrating nutrition and exercise into PD treatment plans can improve patient outcomes and quality of life.
- Encouraging patient adherence to wellness habits and pharmacological therapy is essential for effective PD management.
Dr. Isaacson discusses how physicians can effectively integrate wellness strategies such as nutrition and exercise into treatment plans for Parkinson's disease (PD), encourage patient adherence to these habits alongside pharmacological therapy, and leverage advocacy groups as vital resources for both patients and health care professionals (HCPs) in navigating wellness and care management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How should physicians integrate wellness strategies, such as nutrition and exercise, into the treatment plans for patients with PD?
- What should HCPs do to encourage patients to adopt and maintain wellness habits and comply with pharmacological therapy for PD?
- What is the role of advocacy groups for patients in navigating PD, especially in adopting and encouraging wellness habits?
- How can HCPs leverage these resources in their practices?
- Are there any advocacy groups that are focused on HCPs in PD?
Advertisement
Related to this article
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
2
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
3
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
4
From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026
5